Summary: We aimed to determine patients’ reasons for continuing alendronate therapy over 5 years by administering a questionnaire. Bone mineral density, fractures, drugs, Charlson comorbidity index, and lifestyle factors were also considered. Education and awareness of the disease appeared highly associated with good alendronate adherence while worsening health status with discontinuation. Introduction: Aim of this study was to investigate patients’ reasons for adhering to long-term alendronate therapy (more than 5 years), as data is not available in the current literature regarding the reasons behind long-term adherence. Methods: We studied 204 long-term adherent alendronate users: 65 postmenopausal outpatients still adherent (group C, years on treatment = 8.70 ± 1.31) were compared to 139 age-matched patients who discontinued therapy (group S, years on treatment = 8.64 ± 1.43). We evaluated main biochemical parameters, BMD values, fractures, and Charlson comorbidity index (CCI). A questionnaire was administered to analyze the reasons for long-term adherence. Results: There were no significant differences between groups concerning baseline DXA values, number of fractures, and CCI. A higher education level was observed in group C (C 54% vs S 35% of patients, p = 0.001). At the time of interview, there was a significantly higher number of patients with a CCI of two in group S compared to the beginning of treatment (56% vs 43%, p = 0.04), together with a higher number of patients taking more than 3 drugs (22% vs 11%, p = 0.01) compared to basal evaluation. Forty-seven percent of patients reported new diseases during the treatment as the main reason for stopping alendronate. A multivariate, stepwise logistic regression analysis showed that awareness of the disease was highly associated with adherence (OR = 0.20; 95% CI 0.045–0.93, p = 0.04) followed by higher education (OR = 0.526, 95% CI 0.345–0.801, p = 0.003). Worsening of CCI was associated with discontinuation (OR = 2.75, 95% CI 1.033–7.324, p = 0.04). Conclusions: Education and disease awareness are associated with long-term alendronate adherence while competing health problems negatively impact adherence.

Patients’ reasons for adhering to long-term alendronate therapy / Pepe, J.; Cipriani, C.; Cecchetti, V.; Ferrara, C.; Della Grotta, G.; Danese, V.; Colangelo, L.; Minisola, S.. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 30:8(2019), pp. 1627-1634. [10.1007/s00198-019-05010-w]

Patients’ reasons for adhering to long-term alendronate therapy

Pepe J.
Primo
;
Cipriani C.
Secondo
;
Cecchetti V.;Ferrara C.;Della Grotta G.;Danese V.;Colangelo L.
Penultimo
;
Minisola S.
Ultimo
2019

Abstract

Summary: We aimed to determine patients’ reasons for continuing alendronate therapy over 5 years by administering a questionnaire. Bone mineral density, fractures, drugs, Charlson comorbidity index, and lifestyle factors were also considered. Education and awareness of the disease appeared highly associated with good alendronate adherence while worsening health status with discontinuation. Introduction: Aim of this study was to investigate patients’ reasons for adhering to long-term alendronate therapy (more than 5 years), as data is not available in the current literature regarding the reasons behind long-term adherence. Methods: We studied 204 long-term adherent alendronate users: 65 postmenopausal outpatients still adherent (group C, years on treatment = 8.70 ± 1.31) were compared to 139 age-matched patients who discontinued therapy (group S, years on treatment = 8.64 ± 1.43). We evaluated main biochemical parameters, BMD values, fractures, and Charlson comorbidity index (CCI). A questionnaire was administered to analyze the reasons for long-term adherence. Results: There were no significant differences between groups concerning baseline DXA values, number of fractures, and CCI. A higher education level was observed in group C (C 54% vs S 35% of patients, p = 0.001). At the time of interview, there was a significantly higher number of patients with a CCI of two in group S compared to the beginning of treatment (56% vs 43%, p = 0.04), together with a higher number of patients taking more than 3 drugs (22% vs 11%, p = 0.01) compared to basal evaluation. Forty-seven percent of patients reported new diseases during the treatment as the main reason for stopping alendronate. A multivariate, stepwise logistic regression analysis showed that awareness of the disease was highly associated with adherence (OR = 0.20; 95% CI 0.045–0.93, p = 0.04) followed by higher education (OR = 0.526, 95% CI 0.345–0.801, p = 0.003). Worsening of CCI was associated with discontinuation (OR = 2.75, 95% CI 1.033–7.324, p = 0.04). Conclusions: Education and disease awareness are associated with long-term alendronate adherence while competing health problems negatively impact adherence.
2019
adherence; alendronate; long-term therapy; osteoporosis
01 Pubblicazione su rivista::01a Articolo in rivista
Patients’ reasons for adhering to long-term alendronate therapy / Pepe, J.; Cipriani, C.; Cecchetti, V.; Ferrara, C.; Della Grotta, G.; Danese, V.; Colangelo, L.; Minisola, S.. - In: OSTEOPOROSIS INTERNATIONAL. - ISSN 0937-941X. - 30:8(2019), pp. 1627-1634. [10.1007/s00198-019-05010-w]
File allegati a questo prodotto
File Dimensione Formato  
Pepe_PatientsReasons_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 242.42 kB
Formato Adobe PDF
242.42 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1283193
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
social impact